was reduced by our share of BeiGene’s net losses of $
394
million and amortization of the basis difference of $
190
million, with such amounts recognized in Other income (expense), net. In addition, during the year ended December 31,
2022, the carrying value increased by $
11
million from the impact of other BeiGene ownership transactions. For information on a collaboration agreement we entered into with BeiGene in connection with this investment, see Note 9, Collaborations.
Subject to certain exceptions or otherwise agreed to by BeiGene, while Amgen holds at least
5.0
% of BeiGene’s outstanding common stock, (A) we may only sell our BeiGene equity investment via: (i) a registered public offering, (ii) a sale under Rule 144 of the Securities Act of 1933 (the “Securities Act”) or (iii) a private sale exempt from registration requirements under the Securities Act, and (B) we may not sell more than
5.0
% of BeiGene’s outstanding common stock in any rolling 12-month period.
Other equity securities
Excluding our equity investments in BeiGene (discussed above) and Neumora (discussed below), we held investments in other equity securities with readily determinable fair values (publicly traded securities)
of $
314
million and
$
494
million
as of December 31, 2024 and 2023, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. For the years ended December 31, 2024, 2023 and 2022, net unrealized gains and losses on publicly traded securities resulted in a net
loss
of
$
21
million
, a net
gain
of
$
98
million
and a net
loss
of
$
165
million
, respectively. Realized gains and losses on publicly traded securities for the years ended December 31, 2024, 2023 and 2022, were
not
material.
We held investments of $
319
million and $
309
million in equity securities without readily determinable fair values as of December 31, 2024 and 2023, respectively, which are included in Other noncurrent ass
ets in the Consolidated Balance Sheets. For the years ended
December 31, 2024, 2023 and 2022
, gains due to upward adjustments and gains realized upon dispositions of these securities were not material.
For the years ended December 31, 2024 and
2023
, downward adjustments were
not
material. For the year ended December 31, 2022, down
ward adjustments to the carrying values of these securities were
$
67
million. Adjustments were based on observable price transactions.
Equity Method Investments
Neumora Therapeutics, Inc.
As of December 31, 2024 and 2023, our ownership interests in Neumora were approximately
21.9
%
and
23.2
%, respectively, and the fair values of our investment were $
375
million and $
603
million, respectively, which are included in Other noncurrent assets in the Consolidated Balance Sheets. Although our equity investment qualifies us for the equity method of accounting, we have elected the fair value option to account for our investment. See Note 18, Fair value measurement. Under the fair value option, changes in the